GET DAILY SIGNALSGSK Reports +5% CER Turnover Growth in Q3 2026 as Specialty Segment Accelerates
Key Takeaways
- GSK reported third-quarter 2026 turnover of £8.9 billion, up 4% at actual exchange rates (AER) and 5% at constant exchange rates (CER).
- Core earnings per share (EPS) came in at 54.6 pence, beating the company-compiled analyst consensus of 50.4 pence.
- Specialty Medicines led the quarter with 15% growth, while Vaccines slipped 2% on lower Arexvy and Shingrix sales.
- Total operating profit fell 16% and total EPS declined 21%, partly reflecting £328 million in restructuring charges tied to the Accelerate Growth programme.
- GSK reaffirmed full-year 2026 guidance for 3% to 5% turnover growth and 7% to 9% core operating profit and core EPS growth.
Why GSK's Q3 Results Matter
GSK plc is one of the world's largest pharmaceutical and vaccines companies, and its third-quarter results offer a key read on whether its specialty medicines strategy is offsetting pressure in its legacy vaccines and general medicines franchises. With the company navigating the gradual loss of exclusivity on its dolutegravir-based HIV portfolio between 2028 and 2030, investors are closely watching how newer launches in oncology, respiratory, and hepatitis B perform. This quarter's report also matters because it tests the durability of GSK's 2031 sales target of more than £40 billion and its ability to sustain shareholder returns through dividends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Q3 Numbers
For the three months ended 30 September 2026, GSK reported total turnover of £8,887 million, up 4% at actual exchange rates and 5% at constant exchange rates. Core operating profit rose 5% at constant exchange rates to £3,076 million, while core EPS (a non-IFRS measure that excludes certain restructuring and other items) increased 1% to 54.6 pence, ahead of the company-compiled analyst consensus of 50.4 pence.
Specialty Medicines delivered sales of £3.9 billion, up 15%, driven by HIV sales of £2.1 billion (+10%), Respiratory, Immunology & Inflammation of £1.1 billion (+21%), and Oncology of £0.6 billion (+23%). Vaccines sales declined 2% to £2.6 billion, with Shingrix down 5% to £0.8 billion and Arexvy down 24% to £0.2 billion, partially offset by a 12% rise in meningitis vaccines. General Medicines were broadly stable at £2.4 billion, with Trelegy up 8%.
Reported (total) operating profit fell 16% to £2,127 million and total EPS fell 21% to 38.5 pence, reflecting £328 million of restructuring charges under the Accelerate Growth programme. Cash generated from operations was £3.1 billion, with free cash flow of £2.1 billion. GSK reaffirmed its full-year 2026 guidance and declared a third-quarter dividend of 17 pence per share.
How the Market Responded
Despite a top-and-bottom-line beat, GSK shares traded lower in early activity following the release, suggesting investors focused on the decline in reported profit and the softer performance in the vaccines franchise rather than the stronger core results. The 21% drop in total EPS, driven largely by restructuring charges, and the continued pressure on Arexvy and Shingrix weighed on sentiment even as Specialty Medicines momentum remained robust. The reaffirmed full-year guidance provided reassurance on the operational outlook, but the market's initial response underscores how closely investors are watching the transition toward higher-growth specialty and oncology products.
Looking Ahead: Guidance and Key Catalysts
GSK reaffirmed its 2026 guidance, expecting turnover growth of 3% to 5% and core operating profit and core EPS growth of 7% to 9% at constant exchange rates. Management indicated it is tracking toward the upper half of its turnover and core operating profit ranges, while core EPS growth is expected toward the lower half of the range. The company also reiterated its 2031 sales outlook of more than £40 billion.
Several catalysts warrant attention in the quarters ahead. The launch of Hibsago, a first-of-its-kind finite treatment for chronic hepatitis B approved in the US and Japan, represents a significant long-term growth opportunity. In oncology, Jideytro has now launched in non-small cell lung cancer, and Jemperli gained an expanded indication in locally advanced rectal cancer. GSK is also on track to initiate 22 phase III trials in 2026, with 18 already started.
Investors should also monitor the ongoing decline in Arexvy, pricing pressures in the US, and the gradual impact of dolutegravir loss of exclusivity beginning in 2028. Cost discipline from the Accelerate Growth programme and the trajectory of newer specialty launches will be central to whether GSK can sustain its growth momentum while maintaining its dividend policy, which targets 70 pence per share for the full year 2026. From what I see, the data from Tickeron’s AI Daily Buy/Sell Signals aligns with this cautious optimism around the specialty pipeline.
Using Tickeron’s AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Screener to filter stocks by industry, technical patterns, and fundamentals. It helps surface comparable names and confirm how earnings movers like GSK stack up against peers without manual effort. The tool has become a reliable part of my workflow for earnings season reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for GSK turns positive, indicating new upward trend
GSK saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 49 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on October 15, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 24 of 45 cases over the following month. The odds of a continued upward trend are 53%.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GSK moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.534) is normal, around the industry mean (-2.729). P/E Ratio (20.325) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.037) settles around the average of (0.040) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement